Use of a calcium sulfate-calcium phosphate synthetic bone graft composite in the surgical management of primary bone tumors
Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical s...
Saved in:
Published in: | Orthopedics (Thorofare, N.J.) Vol. 36; no. 2; pp. e216 - e222 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
SLACK INCORPORATED
01-02-2013
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate-calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate-calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm(3). Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm(3). Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate-calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate-calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors. |
---|---|
AbstractList | Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate-calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate-calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm(3). Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm(3). Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate-calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate-calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors. Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate-calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate-calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm super(3). Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm super(3). Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate-calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate-calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors. Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate--calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate--calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm3 . Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm3 . Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate--calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate--calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors. Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate–calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate–calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm 3 . Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm 3 . Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate–calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate–calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors. |
Author | Finlay, Karen Jurriaans, Erik Evaniew, Nathan Deheshi, Benjamin Ghert, Michelle Tan, Victoria Parasu, Naveen |
Author_xml | – sequence: 1 givenname: Nathan surname: Evaniew fullname: Evaniew, Nathan organization: Department of Surgery, Division of Orthopaedics, McMaster University, Hamilton, Ontario, Canada – sequence: 2 givenname: Victoria surname: Tan fullname: Tan, Victoria – sequence: 3 givenname: Naveen surname: Parasu fullname: Parasu, Naveen – sequence: 4 givenname: Erik surname: Jurriaans fullname: Jurriaans, Erik – sequence: 5 givenname: Karen surname: Finlay fullname: Finlay, Karen – sequence: 6 givenname: Benjamin surname: Deheshi fullname: Deheshi, Benjamin – sequence: 7 givenname: Michelle surname: Ghert fullname: Ghert, Michelle |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23380017$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1v3CAQhlG0UbL5-AdRhNRLLm6YAQx7rKJ8VIrUS3O2MAu7jmzjgn1Y9c8HZ3dz6KUnNMzzvgPzXpBFH3pHyA2w73yF-p6BUEoIVSADzgCxQHlClrDiukBeqgVZzkgxM-fkIqV3xhhXoM_IOXKuGQO1JH_fkqPBU0OtaW0zdTRNrTejK471sA1p2OYbmnb9uHVjY2mdn0I30fiR2tANITW53fQ0t7M-bpospp3pzcZ1rh_nAUNsOhN3e-k4dSGmK3LqTZvc9eG8JG9Pj78fXorXX88_H368FpaXeiwQLDfo0Rmja7mWiKiErb2HUjMwALY0pgbhkUm-ltKupBTGOiuULWu_5pfkbu87xPBncmmsuiZZ17amd2FKFfDsqUFJ_X8UtSgRQWFGv_2Dvocp9vkjnxTTACgzJfaUjSGl6Hx1WEQFrJpzrI45Vsccq0_Z7cF8qju3_hIdg-MfNZ2a-Q |
CODEN | ORTHDK |
CitedBy_id | crossref_primary_10_1542_pir_2015_0128 crossref_primary_10_1002_jbm_b_34132 crossref_primary_10_3390_bioengineering10020208 crossref_primary_10_1007_s10856_017_6017_1 crossref_primary_10_1089_ten_teb_2018_0381 crossref_primary_10_1007_s00256_015_2189_2 crossref_primary_10_1016_j_rboe_2017_04_003 crossref_primary_10_1016_j_bea_2023_100107 crossref_primary_10_1016_j_proeng_2014_09_048 crossref_primary_10_3928_01477447_20181023_03 crossref_primary_10_1186_s12891_017_1623_0 crossref_primary_10_3390_antibiotics11070969 crossref_primary_10_2106_JBJS_M_01332 crossref_primary_10_1016_j_carj_2014_11_004 crossref_primary_10_3390_nano13152219 crossref_primary_10_1002_jor_24046 crossref_primary_10_1002_jbm_b_34700 crossref_primary_10_3390_polym14030547 crossref_primary_10_1186_s12891_015_0828_3 crossref_primary_10_3390_ma15030827 crossref_primary_10_3390_ijms23147590 crossref_primary_10_3390_ani14101460 crossref_primary_10_1177_0885328219849712 crossref_primary_10_7547_17_020 crossref_primary_10_1177_11207000231212423 crossref_primary_10_5005_jp_journals_10024_3337 crossref_primary_10_1177_2041731418776819 crossref_primary_10_1002_jbm_b_34318 crossref_primary_10_1002_jor_24508 crossref_primary_10_7759_cureus_20002 crossref_primary_10_1016_j_clineuro_2016_12_011 crossref_primary_10_1177_10225536241254200 crossref_primary_10_1007_s10856_014_5344_8 crossref_primary_10_1016_j_injury_2021_11_057 crossref_primary_10_1097_BPO_0000000000001680 crossref_primary_10_5371_hp_2021_33_3_167 crossref_primary_10_1016_j_tcr_2021_100405 crossref_primary_10_1098_rsos_191830 crossref_primary_10_1111_os_12509 crossref_primary_10_1021_acsabm_8b00221 crossref_primary_10_1016_j_cden_2019_12_006 crossref_primary_10_1007_s10561_016_9582_5 crossref_primary_10_1016_j_msec_2020_111032 crossref_primary_10_3390_molecules26103007 crossref_primary_10_1016_j_jmbbm_2015_07_027 crossref_primary_10_1039_D4TB00262H crossref_primary_10_1038_s41598_017_02048_w crossref_primary_10_1007_s10856_017_5940_5 crossref_primary_10_1586_14737140_2014_901891 crossref_primary_10_3390_jfb12040056 crossref_primary_10_1016_j_rbo_2016_07_014 crossref_primary_10_5397_cise_2022_00969 crossref_primary_10_1007_s00270_023_03390_5 crossref_primary_10_1177_1947603518770249 crossref_primary_10_1016_j_ceramint_2014_03_059 crossref_primary_10_1021_acsbiomaterials_3c00399 |
Cites_doi | 10.1097/01.blo.0000160024.06739.ff 10.1007/s11999-012-2251-5 10.1097/00005131-200203000-00001 10.1097/00003086-199603000-00011 10.1002/jbm.10268 10.1007/s00256-010-1037-7 10.1097/01.blo.0000150371.77314.52 10.1016/j.ocl.2005.08.005 10.1007/s00264-006-0156-1 10.3928/01477447-20080801-31 10.4103/0019-5413.39588 10.1097/BLO.0b013e318059b902 10.1563/1548-1336-35.1.28 10.1007/s00432-008-0427-x 10.2106/00004623-199412000-00009 10.3928/0147-7447-20010201-19 10.2106/00004623-199906000-00008 10.3928/0147-7447-20040102-11 10.1177/230949901001800111 10.5435/00124635-201009000-00009 10.1097/01.blo.0000174684.85250.b5 10.1016/0030-4220(64)90372-X 10.1111/j.1708-8208.2009.00221.x 10.2174/1874325000802010091 10.1177/230949900801600116 10.2106/00004623-199311000-00009 10.1097/00003086-200204000-00029 |
ContentType | Journal Article |
Copyright | Copyright 2013, SLACK Incorporated. Copyright 2013, SLACK Incorporated |
Copyright_xml | – notice: Copyright 2013, SLACK Incorporated. – notice: Copyright 2013, SLACK Incorporated |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88E 88I 8AF 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. KB0 M0S M1P M2P NAPCQ PQEST PQQKQ PQUKI PRINS Q9U S0X 7X8 7QP |
DOI | 10.3928/01477447-20130122-25 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic SIRS Editorial MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Central Student ProQuest Central Essentials SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
DatabaseTitleList | MEDLINE Calcium & Calcified Tissue Abstracts ProQuest Central Student CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1938-2367 |
EndPage | e222 |
ExternalDocumentID | 2882851941 10_3928_01477447_20130122_25 23380017 |
Genre | Journal Article |
GroupedDBID | --- .GJ 04C 0R~ 123 29N 29O 36B 3V. 4.4 53G 5RE 6PF 7RV 7X7 88E 88I 8AF 8AO 8FI 8FJ AAQQT AAWTL ABJNI ABPPZ ABUWG ACGFS ACGOD ADBBV ADFRT ADOJX AENEX AFKRA AHMBA AKWKQ ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BENPR BKEYQ BMSDO BPHCQ BVXVI C45 CCPQU CGR CUY CVF DU5 DWQXO EBD EBS ECM ECT EIF EIHBH EJD EMB EMOBN EX3 F5P FYUFA GNUQQ HCIFZ HMCUK HZ~ IAO IHR INH IPT ITC M1P M2P M2Q N4W NAPCQ NPM O9- OVD PCD PQQKQ PROAC PSQYO RWG RWL S0X SJN SV3 TAE TEORI UKHRP WH7 WOW XFW YCJ ZCN ZGI ZXP AAYXX CITATION 7XB 8FK K9. PQEST PQUKI PRINS Q9U 7X8 7QP |
ID | FETCH-LOGICAL-c368t-21c3a2f2eaa8b5d522274cbff16801a11c6aab14f2053d55c9554acec47c6bfd3 |
ISSN | 0147-7447 |
IngestDate | Fri Oct 25 05:48:06 EDT 2024 Sat Oct 05 04:39:48 EDT 2024 Thu Oct 10 15:59:27 EDT 2024 Thu Nov 21 21:56:51 EST 2024 Sat Sep 28 07:53:10 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Copyright 2013, SLACK Incorporated. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c368t-21c3a2f2eaa8b5d522274cbff16801a11c6aab14f2053d55c9554acec47c6bfd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 23380017 |
PQID | 1284081125 |
PQPubID | 40235 |
PageCount | 1 |
ParticipantIDs | proquest_miscellaneous_1352281758 proquest_miscellaneous_1284622172 proquest_journals_1284081125 crossref_primary_10_3928_01477447_20130122_25 pubmed_primary_23380017 |
PublicationCentury | 2000 |
PublicationDate | 2013-Feb 2013-02-00 20130201 |
PublicationDateYYYYMMDD | 2013-02-01 |
PublicationDate_xml | – month: 02 year: 2013 text: 2013-Feb |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Thorofare |
PublicationTitle | Orthopedics (Thorofare, N.J.) |
PublicationTitleAlternate | Orthopedics |
PublicationYear | 2013 |
Publisher | SLACK INCORPORATED |
Publisher_xml | – name: SLACK INCORPORATED |
References | Kelly CM (e_1_3_1_21_2) 2004; 27 e_1_3_1_22_2 e_1_3_1_23_2 e_1_3_1_24_2 e_1_3_1_8_2 e_1_3_1_7_2 e_1_3_1_9_2 e_1_3_1_20_2 e_1_3_1_4_2 e_1_3_1_29_2 e_1_3_1_3_2 McCanless J (e_1_3_1_18_2) 2009; 33 e_1_3_1_6_2 Campanacci M (e_1_3_1_5_2) 1990; 75 e_1_3_1_25_2 e_1_3_1_26_2 e_1_3_1_2_2 e_1_3_1_27_2 e_1_3_1_28_2 e_1_3_1_13_2 e_1_3_1_12_2 e_1_3_1_11_2 e_1_3_1_30_2 e_1_3_1_10_2 e_1_3_1_17_2 e_1_3_1_16_2 e_1_3_1_15_2 e_1_3_1_14_2 e_1_3_1_19_2 |
References_xml | – ident: e_1_3_1_4_2 doi: 10.1097/01.blo.0000160024.06739.ff – ident: e_1_3_1_22_2 doi: 10.1007/s11999-012-2251-5 – ident: e_1_3_1_17_2 doi: 10.1097/00005131-200203000-00001 – ident: e_1_3_1_6_2 doi: 10.1097/00003086-199603000-00011 – ident: e_1_3_1_16_2 doi: 10.1002/jbm.10268 – ident: e_1_3_1_14_2 doi: 10.1007/s00256-010-1037-7 – volume: 75 start-page: 212 issue: 1 year: 1990 ident: e_1_3_1_5_2 article-title: Curettage of giant cell tumor of bone. reconstruction with subchondral grafts and cement publication-title: Chir Organi Mov contributor: fullname: Campanacci M – volume: 33 start-page: 99 year: 2009 ident: e_1_3_1_18_2 article-title: Comparison of bone graft substitutes through protein adsorption and cellular response publication-title: Trans Orthop Res Soc contributor: fullname: McCanless J – ident: e_1_3_1_8_2 doi: 10.1097/01.blo.0000150371.77314.52 – ident: e_1_3_1_23_2 doi: 10.1016/j.ocl.2005.08.005 – ident: e_1_3_1_27_2 doi: 10.1007/s00264-006-0156-1 – ident: e_1_3_1_30_2 doi: 10.3928/01477447-20080801-31 – ident: e_1_3_1_29_2 doi: 10.4103/0019-5413.39588 – ident: e_1_3_1_12_2 doi: 10.1097/BLO.0b013e318059b902 – ident: e_1_3_1_13_2 doi: 10.1563/1548-1336-35.1.28 – ident: e_1_3_1_19_2 doi: 10.1007/s00432-008-0427-x – ident: e_1_3_1_20_2 doi: 10.2106/00004623-199412000-00009 – ident: e_1_3_1_26_2 doi: 10.3928/0147-7447-20010201-19 – ident: e_1_3_1_2_2 doi: 10.2106/00004623-199906000-00008 – volume: 27 start-page: s131 issue: 1 year: 2004 ident: e_1_3_1_21_2 article-title: Treatment of benign bone lesions with an injectable calcium sulfate-based bone graft substitute publication-title: Orthopedics doi: 10.3928/0147-7447-20040102-11 contributor: fullname: Kelly CM – ident: e_1_3_1_24_2 doi: 10.1177/230949901001800111 – ident: e_1_3_1_11_2 doi: 10.5435/00124635-201009000-00009 – ident: e_1_3_1_7_2 doi: 10.1097/01.blo.0000174684.85250.b5 – ident: e_1_3_1_15_2 doi: 10.1016/0030-4220(64)90372-X – ident: e_1_3_1_25_2 doi: 10.1111/j.1708-8208.2009.00221.x – ident: e_1_3_1_9_2 doi: 10.2174/1874325000802010091 – ident: e_1_3_1_28_2 doi: 10.1177/230949900801600116 – ident: e_1_3_1_3_2 doi: 10.2106/00004623-199311000-00009 – ident: e_1_3_1_10_2 doi: 10.1097/00003086-200204000-00029 |
SSID | ssj0003718 |
Score | 2.2895668 |
Snippet | Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | e216 |
SubjectTerms | Activities of daily living Adolescent Adult Bone Neoplasms - surgery Bone Substitutes Bone Transplantation Calcium Phosphates Calcium Sulfate Curettage Cysts Disease transmission Ethics Female Humans Male Middle Aged Morbidity Patients Reconstructive Surgical Procedures Retrospective Studies Tumors Young Adult |
Title | Use of a calcium sulfate-calcium phosphate synthetic bone graft composite in the surgical management of primary bone tumors |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23380017 https://www.proquest.com/docview/1284081125 https://search.proquest.com/docview/1284622172 https://search.proquest.com/docview/1352281758 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6y4ULAvEqLMhI3FAWYjtpekTQ1apadZE2RXuLHMehFWpT5cGFP8-M7TjZFaDlwCVKncSJPF_H34xnxoS8FQmYJkKyQMzyKBBznQeyyD8ExSzKYxWBWWSKuJ5fzVbXyeeFWEwm_aYlQ9t_lTS0gawxc_YfpO07hQY4B5nDEaQOxzvJfW2d8_IdDL7adjuMPy-BUAb978Omag4baMFqBUD_sGJrXgHX_FbLsjUx5hjIpfsIyKarrXbc-UgZEybtylSYR9tuV7llIUd0L-t2Ux1wFci4ddNNBQpfWof36nR5OvJAIJk3FW1R16Mnf_AmGJX4dYsLC1s_f3yRtWw6e_sPPaSyLdGbKZ1hAPr9-9ijgbtL-OgQbbXwHLQwlpYbq2lbJ8XBkY10rmZhPJq_NbOJzrfnBiCCLt8BGC-Wp8A12xBMcZt4fbMU9-oyO1tfXGTp4jo9IvcYaDFUolfLlZ_mOczqNhcTe37_u35vcp0_GDCGyKQPyQNngdCPFjqPyETvH5OfABtalVRSBxN6CzbUw4Z62FCUPTWwoR42dLuncJn2sKEDbPAFDjb2UQubJ2R9tkg_nQduX45A8ThpAxYqLlnJtJRJHhURplMLlZdlGAPfkWGoYinzUJQMNHwRRWoOnFUqrcRMxXlZ8KfkeA9veU4o5wJ9DCoBO1cUhZAxU1qoGOz4hPNyPiVBP4KZ-8AMzFYc8awf8awf8YxFU3LSD3Pm_pRNhhQMmG-Il9_4y6BGcW1M7nXV2Xtihru1_eUeNFYS4NvJlDyzIvQfxThPkPG9uMMbXpL7A-xPyHFbd_oVOWqK7rWB2C89eacr |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Multiple Vendors |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+a+calcium+sulfate-calcium+phosphate+synthetic+bone+graft+composite+in+the+surgical+management+of+primary+bone+tumors&rft.jtitle=Orthopedics+%28Thorofare%2C+N.J.%29&rft.au=Evaniew%2C+Nathan&rft.au=Tan%2C+Victoria&rft.au=Parasu%2C+Naveen&rft.au=Jurriaans%2C+Erik&rft.date=2013-02-01&rft.eissn=1938-2367&rft.volume=36&rft.issue=2&rft.spage=e216&rft.epage=e222&rft_id=info:doi/10.3928%2F01477447-20130122-25&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0147-7447&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0147-7447&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0147-7447&client=summon |